中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2014年
z1期
23-25
,共3页
三维适形放疗%替吉奥%食管癌
三維適形放療%替吉奧%食管癌
삼유괄형방료%체길오%식관암
Three-dimensional conformal radiotherapy%S-l%EsophaGus carcinoma
目的：观察三维适形放疗（3-DCRT ）联合替吉奥治疗老年局部晚期食管癌患者的疗效。方法54例经病理学证实的老年局部晚期食管癌患者，按随机、对照的原则分为实验组（27例，采用3-DCRT联合替吉奥化疗增敏）和对照组（27例，采用单独3-DCRT）。结果实验组完全缓解率和总有效率分别为62.96%和85. l9%，均明显高于对照组33.33%和59.26%（χ2=4.75，P=0.029；χ2=4.52，P=0.033）；实验组23例患者吞咽困难症状均获得缓解（l00%，23/23），对照组吞咽困难22例中的l6例患者症状获得缓解（72.3%，l6/22），两组比较差异有统计学意义（χ2=7.24，P=0.007）；实验组的l、2年生存率分别为74. l%和54.8%，均明显高于对照组的55.6%和36. l%（χ2=3.9l，P =0.047；χ2=3.98，P=0.046）；实验组和对照组分别有26例（96%）和24例（89%）出现Ⅱ级或以下毒副作用，差异无统计学意义（χ2=l.08，P=0.299）。结论3-DCRT联合替吉奥治疗老年局部晚期食管癌患者的完全缓解率、总有效率和l、2年生存率均较单纯3-DCRT明显提高，且不良反应可以耐受。
目的：觀察三維適形放療（3-DCRT ）聯閤替吉奧治療老年跼部晚期食管癌患者的療效。方法54例經病理學證實的老年跼部晚期食管癌患者，按隨機、對照的原則分為實驗組（27例，採用3-DCRT聯閤替吉奧化療增敏）和對照組（27例，採用單獨3-DCRT）。結果實驗組完全緩解率和總有效率分彆為62.96%和85. l9%，均明顯高于對照組33.33%和59.26%（χ2=4.75，P=0.029；χ2=4.52，P=0.033）；實驗組23例患者吞嚥睏難癥狀均穫得緩解（l00%，23/23），對照組吞嚥睏難22例中的l6例患者癥狀穫得緩解（72.3%，l6/22），兩組比較差異有統計學意義（χ2=7.24，P=0.007）；實驗組的l、2年生存率分彆為74. l%和54.8%，均明顯高于對照組的55.6%和36. l%（χ2=3.9l，P =0.047；χ2=3.98，P=0.046）；實驗組和對照組分彆有26例（96%）和24例（89%）齣現Ⅱ級或以下毒副作用，差異無統計學意義（χ2=l.08，P=0.299）。結論3-DCRT聯閤替吉奧治療老年跼部晚期食管癌患者的完全緩解率、總有效率和l、2年生存率均較單純3-DCRT明顯提高，且不良反應可以耐受。
목적：관찰삼유괄형방료（3-DCRT ）연합체길오치료노년국부만기식관암환자적료효。방법54례경병이학증실적노년국부만기식관암환자，안수궤、대조적원칙분위실험조（27례，채용3-DCRT연합체길오화료증민）화대조조（27례，채용단독3-DCRT）。결과실험조완전완해솔화총유효솔분별위62.96%화85. l9%，균명현고우대조조33.33%화59.26%（χ2=4.75，P=0.029；χ2=4.52，P=0.033）；실험조23례환자탄인곤난증상균획득완해（l00%，23/23），대조조탄인곤난22례중적l6례환자증상획득완해（72.3%，l6/22），량조비교차이유통계학의의（χ2=7.24，P=0.007）；실험조적l、2년생존솔분별위74. l%화54.8%，균명현고우대조조적55.6%화36. l%（χ2=3.9l，P =0.047；χ2=3.98，P=0.046）；실험조화대조조분별유26례（96%）화24례（89%）출현Ⅱ급혹이하독부작용，차이무통계학의의（χ2=l.08，P=0.299）。결론3-DCRT연합체길오치료노년국부만기식관암환자적완전완해솔、총유효솔화l、2년생존솔균교단순3-DCRT명현제고，차불량반응가이내수。
Objective To investiGate the efficacy of three-dimensional conformal radiotherapy( 3-DCRT)combined with concurrent S-l for locally advanced esophaGus carcinoma in the elderly. Methods Fifty-four elderly patients with locally advanced esophaGus carcinoma were randomly divided into test Group(27 cases treated with 3-DCRT combined with S-l)and control Group(27 cases treated with 3-DCRT alone). DiaGnosis in all cases was confirmed by patholoGy. Results The complete remission rate and overall efficiency rate in test Group were 62. 96% and 85. l9% respectively,and 33. 33% and 59. 26% in control Group(χ2 =4. 75,P=0. 029;χ2 =4. 52,P=0. 033). All 23 patients with dysphaGia in test Group were in remission,and l6 of 22 patients with dysphaGia in control Group were in remission,and there was statistical siGnificant difference between two Groups(χ2 =7. 24,P=0. 007). The one-and two-year survival rates in test Group were 74. l% and 54. 8%respectively,and 55. 6% and 36. l% in control Group(χ2 =3. 9l,P=0. 047;χ2 =3. 98,P=0. 046). Toxicities of Grade 0-Ⅱ in both Groups were similar,and there was no statistical siGnificant difference(χ2 =l. 08,P=0. 299). Conclusion The complete remission rate,overall efficiency rate and one-and two-year survival rates of 3-DCRT combined with concurrent S-l were siGnificant hiGher than 3-DCRT alone in the treatment for the elderly patients with locally advanced esophaGus carcinoma. And ti’s adverse effects were well tolerated.
